Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2005.063412v1, 2006; 10.1373/clinchem.2005.063412
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.063412v1
52/3/453    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charlton-Menys, V.
Right arrow Articles by Durrington, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charlton-Menys, V.
Right arrow Articles by Durrington, P. N.

Received on November 8, 2005
Accepted on December 14, 2005

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Semiautomated Method for Determination of Serum Paraoxonase Activity Using Paraoxon as Substrate

Valentine Charlton-Menys 1*, Yifen Liu 1, Paul N. Durrington 1

1 Division of Cardiovascular and Endocrine Sciences, Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom

* To whom correspondence should be addressed. E-mail: valentine.menys{at}cmmc.nhs.uk.

Background: Serum paraoxonase (PON1) is an enzyme associated with HDL, and its ability to protect LDL from oxidation is one mechanism by which HDL protects against atherosclerosis. Low concentrations of PON1 are found in patients with type 2 diabetes or coronary heart disease. Serum PON1 activity may also be important in avoidance of organophosphate toxicity in industry.

Methods: The generally accepted method for determining PON1 activity requires use of a recording spectrophotometer and is not suited to large numbers of samples; in addition, automation presents particular problems because of the extreme toxicity of substrates such as paraoxon. We established a relatively safe microtiter plate method that facilitates the determination of PON1 activity at a rate of 120 samples per hour.

Results: PON1 activity was determined by the generally accepted method (x) and the new method (y); results correlated with a slope close to unity (y = 0.93x + 8; r = 0.97; P <0.0001; n = 101). Examination of differences by Bland-Altman plots showed a weak concentration-dependent difference (r = 0.33; P <0.0001; n = 101). The intra- and interassay sample CVs, obtained with samples with PON1 activities ranging from 41 to 348 nmol · min-1 · mL-1, were 3.5% and 2.7%, respectively (n = 16).

Conclusion:The proposed method for determination of PON activity is simple, relatively safe, and inexpensive and is suitable for analysis of large numbers of samples.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Lipid Res.Home page
J. M. Proudfoot, A. E. Barden, W. M. Loke, K. D. Croft, I. B. Puddey, and T. A. Mori
HDL is the major lipoprotein carrier of plasma F2-isoprostanes
J. Lipid Res., April 1, 2009; 50(4): 716 - 722.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.